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The Post-COVID-19 Functional Status
scale: a tool to measure functional status
over time after COVID-19
To the Editor:
Since the outbreak of the coronavirus disease 2019 (COVID-19) pandemic, most attention has focused on
containing transmission of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and
addressing the surge of critically ill patients in acute care settings. Indeed, as of 29 April 2020, over
3 million confirmed cases have been accounted for globally [1]. In the coming weeks and months,
emphasis will gradually involve also post-acute care of COVID-19 survivors. It is anticipated that
COVID-19 may have a major impact on physical, cognitive, mental and social health status, also in
patients with mild disease presentation [2]. Previous outbreaks of coronaviruses have been associated with
persistent pulmonary function impairment, muscle weakness, pain, fatigue, depression, anxiety, vocational
problems, and reduced quality of life to various degrees [3–5].
Given the heterogeneity of COVID-19 in terms of clinical and radiological presentation, it is pivotal to
have a simple tool to monitor the course of symptoms and the impact of symptoms on the functional
status of patients, i.e. a scale that can measure the consequence of the disease beyond binary outcomes
such as mortality. In view of the massive number of COVID-19 survivors that require follow-up, an easy
and reproducible instrument to identify those patients suffering from slow or incomplete recovery would
help in guiding considered use of medical resources and will also standardise research efforts.
The optimal instrument for this purpose is an ordinal scale assessing the full range of functional
limitations to capture the heterogeneity of post-COVID-19 outcomes. Ordinal scales rank patients in
meaningful categories and do not differentiate between underlying causes to be of general value. These
scales can be used to track improvement over time and answer meaningful clinical questions (e.g. “How
will I come out of this corona infection?”) or for research purposes. They may be either self-reported or
assessed in a formal standardised interview [6].
Recently, our group proposed an ordinal scale for assessment of patient-relevant functional limitations
following an episode of venous thromboembolism (VTE): the post-VTE functional status (PVFS) scale
[7, 8]. It covers the full spectrum of functional outcomes, and focuses on both limitations in usual duties/
activities and changes in lifestyle in six scale grades. In short, grade 0 reflects the absence of any functional
limitation, and the death of a patient is recorded in grade D. From grade 1 upwards, symptoms, pain or
anxiety are present to an increasing degree. This has no effect on activities for patients in grade 1, whereas
a lower intensity of the activities is required for those in grade 2. Grade 3 accounts for inability to perform
certain activities, forcing patients to structurally modify these. Finally, grade 4 is reserved for those patients
with severe functional limitations requiring assistance with activities of daily living. This scale was
developed after discussion with international experts (via a Delphi analysis) with input from patients (via
patient focus groups). The inter-observer agreement of scale grade assignment was shown to be
good-to-excellent with kappas of 0.75 (95% CI 0.58–1.0) and 1.0 (95% CI 0.83–1.0) between self-reported
values and independent raters, respectively [7].
The idea of using ordinal scales for COVID-19 research is not new. The World Health Organization
proposed the “Ordinal Scale for Clinical Improvement” on 18 February 2020 [9], with categories mainly
based on the type of treatment, to be used as the primary end-point in acute-phase trials
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(e.g. NCT04292899 and NCT04351724). However, due to its focus on in-hospital treatment, this scale is
not a useful measure of the long-term outcomes of COVID-19 and its treatment after discharge.
There is a high incidence of pulmonary embolism itself, alongside myocardial damage/myocarditis and
neurological complications, in critically ill patients with COVID-19 [10, 11]. Therefore, we consider our
PVFS scale (after slight adaptation) to be useful in the current COVID-19 pandemic too (figure 1). The
proposed “Post-COVID-19 Functional Status (PCFS) scale” could be assessed upon discharge from the
hospital, at 4 and 8 weeks post-discharge to monitor direct recovery, and at 6 months to assess functional
sequelae. We have implemented the scale in our own clinical practices in Leiden University Medical
Center and Kantonsspital Winterthur, and are planning to incorporate it in the LEOSS registry (Lean
European Open Survey on SARS-CoV-2 Infected Patients; https://LEOSS.net) and Maastricht University
Medical Center. Notably, the scale is not meant to replace other relevant instruments for measuring
quality of life, tiredness or dyspnoea in the acute phase, but to be used as an additional outcome measure
to evaluate the ultimate consequences of COVID-19 on functional status. We acknowledge that this “PCFS
scale” is currently not validated, and its usefulness will depend on the local conditions under which it is
implemented. However, if implemented alongside existing outcomes, we will be able to generate sufficient
evidence to make formal conclusions on its use to guide post-COVID-19 care.
This correspondence is a call for action to use and validate ordinal scales such as the one proposed by us
for determining functional recovery from COVID-19. The full manual for patients and physicians or study
personnel is available from https://osf.io/qgpdv/ (free of charge).
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Can you live alone without any assistance from another person?
(e.g. independently being able to eat, walk, use the toilet and manage routine daily hygiene)
a) b)
Are there any duties/activities at home or at work which you are 
no longer able to perform yourself?
Do you suffer from
symptoms, pain, depression or anxiety?
Do you need to avoid or reduce duties/




























How much are you currently affected in 
your everyday life by COVID-19?
(Please indicate which one of the 
following statements applies to you most)
I have no limitations in my everyday life and 
no symptoms, pain, depression or anxiety 
related to the infection.
I have negligible limitations in my everyday 
life as I can perform all usual duties/
activities, although I still have persistent 
symptoms, pain, depression or anxiety.
I suffer from limitations in my everyday life 
as I occasionally need to avoid or reduce 
usual duties/activities or need to spread 
these over time due to symptoms, pain, 
depression or anxiety. I am, however, able to 
perform all activities without any assistance.
I suffer from limitations in my everyday life 
as I am not able to perform all usual duties/
activities due to symptoms, pain, depression 
or anxiety. I am, however, able to take care of 
myself without any assistance.
I suffer from severe limitations in my everyday 
life: I am not able to take care of myself and 
therefore I am dependent on nursing care 
and/or assistance from another person due to 









FIGURE 1 Patient self-report methods for the Post-COVID-19 Functional Status (PCFS) scale. a) Flowchart. b) Patient questionnaire. Instructions
for use: 1) to assess recovery after the SARS-CoV-2 infection, this PCFS scale covers the entire range of functional limitations, including changes
in lifestyle, sports and social activities; 2) assignment of a PCFS scale grade concerns the average situation of the past week (exception: when
assessed at discharge, it concerns the situation of the day of discharge); 3) symptoms include (but are not limited to) dyspnoea, pain, fatigue,
muscle weakness, memory loss, depression and anxiety; 4) in case two grades seem to be appropriate, always choose the highest grade with the
most limitations; 5) measuring functional status before the infection is optional; 6) alternatively to this flowchart and patient questionnaire, an
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